- Home
- GILD vs SPGI Comparison
GILD vs SPGI Comparison
Compare GILD & SPGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- SPGI
- Stock Information
- Founded
- GILD 1987
- SPGI 1860
- Country
- GILD United States
- SPGI United States
- Employees
- GILD N/A
- SPGI N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- SPGI Finance: Consumer Services
- Sector
- GILD Health Care
- SPGI Finance
- Exchange
- GILD Nasdaq
- SPGI Nasdaq
- Market Cap
- GILD 145.4B
- SPGI 147.7B
- IPO Year
- GILD 1992
- SPGI N/A
- Fundamental
- Price
- GILD $119.79
- SPGI $487.21
- Analyst Decision
- GILD Buy
- SPGI Strong Buy
- Analyst Count
- GILD 22
- SPGI 13
- Target Price
- GILD $120.05
- SPGI $609.31
- AVG Volume (30 Days)
- GILD 6.9M
- SPGI 1.8M
- Earning Date
- GILD 10-30-2025
- SPGI 10-30-2025
- Dividend Yield
- GILD 2.64%
- SPGI 0.78%
- EPS Growth
- GILD 6514.05
- SPGI 21.42
- EPS
- GILD 6.42
- SPGI 13.74
- Revenue
- GILD $29,087,000,000.00
- SPGI $15,012,000,000.00
- Revenue This Year
- GILD $2.25
- SPGI $8.98
- Revenue Next Year
- GILD $3.77
- SPGI $7.21
- P/E Ratio
- GILD $18.65
- SPGI $35.46
- Revenue Growth
- GILD 2.79
- SPGI 9.04
- 52 Week Low
- GILD $86.08
- SPGI $427.14
- 52 Week High
- GILD $124.61
- SPGI $579.05
- Technical
- Relative Strength Index (RSI)
- GILD 55.80
- SPGI 48.06
- Support Level
- GILD $116.81
- SPGI $470.97
- Resistance Level
- GILD $121.58
- SPGI $500.24
- Average True Range (ATR)
- GILD 3.13
- SPGI 9.44
- MACD
- GILD -0.30
- SPGI 2.62
- Stochastic Oscillator
- GILD 54.49
- SPGI 56.91
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About SPGI S&P Global Inc.
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.